Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle

The Cannabinoid CB1 Receptor Antagonist Rimonabant Stimulates 2-Deoxyglucose Uptake in Skeletal Muscle Cells by Regulating the Expression of Phosphatidylinositol-3-kinase

Iolanda Esposito, Maria Chiara Proto, Patrizia Gazzerro, Chiara Laezza, Claudia Miele, Anna Teresa Alberobello, Vittoria D'Esposito, Francesco Beguinot, Pietro Formisano and Maurizio Bifulco
Molecular Pharmacology December 2008, 74 (6) 1678-1686; DOI: https://doi.org/10.1124/mol.108.049205
Iolanda Esposito
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maria Chiara Proto
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Patrizia Gazzerro
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chiara Laezza
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Claudia Miele
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anna Teresa Alberobello
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vittoria D'Esposito
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Francesco Beguinot
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pietro Formisano
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maurizio Bifulco
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

The endocannabinoid system regulates food intake, energy, and glucose metabolism at both central and peripheral levels. We have investigated the mechanism by which it may control glucose uptake in skeletal muscle cells. Detectable levels of the cannabinoid receptor type 1 (CB1) were revealed in L6 cells. Exposure of differentiated L6 myotubes to the CB1 antagonist rimonabant (SR141716) selectively increased 2-deoxyglucose uptake (2-DG) in a time- and dose-dependent manner. A similar effect was induced by genetic silencing of CB1 by small interfering RNA. Protein expression profiling revealed that both the regulatory p85 and the catalytic p110 subunits of the phosphatidylinositol-3-kinase (PI3K) were increased by SR141716. No significant change in the cellular content of other known molecules regulating PI3K was observed. However, phosphoinositide-dependent kinase-1, Akt/protein kinase B, and protein kinase Cζ activities were rapidly induced after SR141716 treatment of L6 cells in a PI3K-dependent manner. The stimulatory effect of SR141716 on PI3K expression and activity was largely prevented by N-[2-(4-bromocinnamylamino)ethyl]-5-isoquinoline (H-89), an inhibitor of the cAMP-dependent protein kinase. Moreover, SR141716-stimulated 2-DG uptake was blunted by the coincubation either with H-89 or with the PI3K inhibitor 2-(4-morpholinyl)-8-phenyl-1(4H)-benzopyran-4-one hydrochloride (LY294002), both in L6 cells and in mouse primary myocytes. Thus, modulation of CB1 regulates glucose uptake at the level of the PI3K signaling system in skeletal muscle cells. Interfering with CB1 signaling may therefore ameliorate glucoregulatory functions in peripheral tissues.

Footnotes

  • This study was supported in part by the European Community's FP6 EUGENE2 (LSHM-CT-2004-512013) and FP7 PREPOBEDIA (number 201-681), grants from the Associazione Italiana per la Ricerca sul Cancro (to F.B. and P.F.), the Ministero dell'Università e della Ricerca Scientifica (to F.B. and P.F. and FIRB Idea Progettuale RBIP0689BS), the Ministero della Salute, the European Federation for the Study of Diabetes, and by the Associazione Educazione e Ricerca Medica Salernitana (ERMES). The financial support of Telethon-Italy is also gratefully acknowledged. I.E. was awarded a travel grant from the Università di Napoli “Federico II”-International Exchange Program.

  • ABBREVIATIONS: T2D, type 2 diabetes; 2-DG, 2-deoxyglucose; PKB, protein kinase B; CB1, cannabinoid receptor type 1; CHX, cycloheximide; CREB, cAMP response element-binding protein; DMEM, Dulbecco's modified Eagle's medium; ECS, endocannabinoid system; GLUT, glucose transporter; IRS, insulin receptor substrate; IRTX, iodoresinatoxin; PeSt, penicillin-streptomycin; PKCζ, protein kinase Cζ; PDK-1, phosphoinositide-dependent kinase-1; PI3K, phosphatidylinositol-3-kinase; PKA, protein kinase A; PTEN, phosphatase and tensin homolog; siRNA, small interfering RNA; SR141716, rimonabant; H-89, N-[2-(4-bromocinnamylamino)ethyl]-5-isoquinoline; LY294002, 2-(4-morpholinyl)-8-phenyl-1(4H)-benzopyran-4-one hydrochloride; PCR, polymerase chain reaction; RT-PCR, reverse transcriptase-polymerase chain reaction; PAGE, polyacrylamide gel electrophoresis.

    • Received May 26, 2008.
    • Accepted September 18, 2008.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Molecular Pharmacology: 74 (6)
Molecular Pharmacology
Vol. 74, Issue 6
1 Dec 2008
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
The Cannabinoid CB1 Receptor Antagonist Rimonabant Stimulates 2-Deoxyglucose Uptake in Skeletal Muscle Cells by Regulating the Expression of Phosphatidylinositol-3-kinase
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

The Cannabinoid CB1 Receptor Antagonist Rimonabant Stimulates 2-Deoxyglucose Uptake in Skeletal Muscle Cells by Regulating the Expression of Phosphatidylinositol-3-kinase

Iolanda Esposito, Maria Chiara Proto, Patrizia Gazzerro, Chiara Laezza, Claudia Miele, Anna Teresa Alberobello, Vittoria D'Esposito, Francesco Beguinot, Pietro Formisano and Maurizio Bifulco
Molecular Pharmacology December 1, 2008, 74 (6) 1678-1686; DOI: https://doi.org/10.1124/mol.108.049205

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

The Cannabinoid CB1 Receptor Antagonist Rimonabant Stimulates 2-Deoxyglucose Uptake in Skeletal Muscle Cells by Regulating the Expression of Phosphatidylinositol-3-kinase

Iolanda Esposito, Maria Chiara Proto, Patrizia Gazzerro, Chiara Laezza, Claudia Miele, Anna Teresa Alberobello, Vittoria D'Esposito, Francesco Beguinot, Pietro Formisano and Maurizio Bifulco
Molecular Pharmacology December 1, 2008, 74 (6) 1678-1686; DOI: https://doi.org/10.1124/mol.108.049205
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Antimicrobial and Antileukemic Transportan 10 Conjugates
  • Pharmacological characterization of zebrafish H1 receptor
  • Bhave and Forman
Show more Articles

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics